Payment overview · 2025
General Payments
$369.98
16 reported records · 5 companies
Healthcare provider profile · identity verified
Robert Wing Chan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALHAMBRA, CA · NPI 1508826488
Verified facts
What the public records show
CMS Open Payments records show Robert Wing Chan, MD received $369.98 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 66.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $244.74 | 66.2% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.80 | 14.3% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $26.61 | 7.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.44 | 6.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.39 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $369.98 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $244.74 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.41 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.80 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 244 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 41 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
110 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
244 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2046 | 415 |
| Losartan Potassium | Losartan Potassium | 1275 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 1271 | 276 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 884 | 159 |
| Farxiga | Dapagliflozin Propanediol | 863 | 147 |
| Metoprolol Succinate | Metoprolol Succinate | 827 | 147 |
| Metformin Hcl | Metformin Hcl | 743 | 149 |
| Alendronate Sodium | Alendronate Sodium | 714 | 126 |
| Montelukast Sodium | Montelukast Sodium | 698 | 158 |
| Icosapent Ethyl | Icosapent Ethyl | 656 | 128 |
| Nifedipine Er | Nifedipine | 654 | 98 |
| Vascepa | Icosapent Ethyl | 645 | 96 |
| Allopurinol | Allopurinol | 577 | 102 |
| Omeprazole | Omeprazole | 515 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 515 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 66 |
| Azelastine Hcl | Azelastine Hcl | 430 | 111 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 415 | 66 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 409 | 161 |
| Gabapentin | Gabapentin | 392 | 100 |
| Dapagliflozin | Dapagliflozin Propanediol | 329 | 94 |
| Metformin Hcl Er | Metformin Hcl | 292 | 60 |
| Famotidine | Famotidine | 291 | 103 |
| Glimepiride | Glimepiride | 288 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 269 | 46 |
| Celecoxib | Celecoxib | 260 | 102 |
| Rybelsus | Semaglutide | 244 | 27 |
| Fluocinonide | Fluocinonide | 229 | 70 |
| Januvia | Sitagliptin Phosphate | 228 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 211 | 61 |
| Finasteride | Finasteride | 201 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 46 |
| Amoxicillin | Amoxicillin | 182 | 133 |
| Donepezil Hcl | Donepezil Hcl | 181 | 29 |
| Fenofibrate | Fenofibrate,micronized | 180 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 157 | 40 |
| Raloxifene Hcl | Raloxifene Hcl | 151 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 148 | 37 |
| Ibandronate Sodium | Ibandronate Sodium | 138 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 132 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 132 | 19 |
| Spironolactone | Spironolactone | 132 | 25 |
| Jardiance | Empagliflozin | 129 | 41 |
| Ezetimibe | Ezetimibe | 126 | 32 |
| Azithromycin | Azithromycin | 114 | 96 |
| Vemlidy | Tenofovir Alafenamide | 110 | 12 |
| Atenolol | Atenolol | 106 | 22 |
| Eliquis | Apixaban | 106 | 17 |
| Nateglinide | Nateglinide | 103 | 16 |
| Cyclosporine | Cyclosporine | 100 | 20 |
| Dexlansoprazole Dr | Dexlansoprazole | 100 | 18 |
| Ozempic | Semaglutide | 99 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 91 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 13 |
| Hydrocortisone | Hydrocortisone | 81 | 23 |
| Creon | Lipase/Protease/Amylase | 79 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 77 | 11 |
| Repaglinide | Repaglinide | 76 | 12 |
| Tradjenta | Linagliptin | 76 | 17 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 73 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 26 |
| Meloxicam | Meloxicam | 71 | 28 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 68 | 27 |
| Carvedilol | Carvedilol | 67 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 67 | 17 |
| Kerendia | Finerenone | 67 | 15 |
| Benazepril Hcl | Benazepril Hcl | 63 | 12 |
| Diclofenac Epolamine | Diclofenac Epolamine | 62 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 59 | suppressed |
| Edarbi | Azilsartan Medoxomil | 58 | suppressed |
| Furosemide | Furosemide | 57 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 11 |
| Lisinopril | Lisinopril | 55 | 13 |
| Sertraline Hcl | Sertraline Hcl | 55 | 13 |
| Clonidine Hcl | Clonidine Hcl | 54 | 14 |
| Fenofibrate | Fenofibrate | 54 | 12 |
| Memantine Hcl Er | Memantine Hcl | 52 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 52 | 20 |
| Valsartan | Valsartan | 50 | suppressed |
| Baclofen | Baclofen | 48 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Sotalol | Sotalol Hcl | 48 | suppressed |
| Methimazole | Methimazole | 47 | suppressed |
| Colchicine | Colchicine | 46 | 12 |
| Myrbetriq | Mirabegron | 46 | 15 |
| Potassium Chloride | Potassium Chloride | 46 | 18 |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 41 | 17 |
| Digoxin | Digoxin | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Naproxen | Naproxen | 41 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Restasis | Cyclosporine | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 39 | suppressed |
| Lorazepam | Lorazepam | 37 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Loperamide | Loperamide Hcl | 36 | 31 |
| Meclizine Hcl | Meclizine Hcl | 36 | 27 |
| Nexium | Esomeprazole Magnesium | 36 | suppressed |
| Procto-Med Hc | Hydrocortisone | 36 | 17 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 36 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Benzonatate | Benzonatate | 32 | 21 |
| Ciclopirox | Ciclopirox | 32 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 16 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 30 | 12 |
| Linzess | Linaclotide | 30 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Prednisone | Prednisone | 29 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Febuxostat | Febuxostat | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Folic Acid | Folic Acid | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ramelteon | Ramelteon | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 20 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Licart | Diclofenac Epolamine | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | 11 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Crestor | Rosuvastatin Calcium | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 11 |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Vigamox | Moxifloxacin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $369.98 · 16 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, Rybelsus | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error